The expression of BRD7 is downregulated or lost in breast, ovarian, pancreatic, nasopharyngeal, and colorectal carcinomas, as well as in lung adenocarcinoma and osteosarcoma [40, 48], an expression pattern that is also described for Hpa2 [49] and is typical for tumor suppressors. Here, BRD7 is linked to osteosarcoma.